Please login to the form below

Not currently logged in
Email:
Password:

Mochida and Wyeth in novel vanilloid pain tie-up

Mochida licenses a portfolio of transient receptor potential vanilloid sub type 1 (TRPV1) receptor antagonists for use as a potential novel treatment for pain to Wyeth Pharmaceuticals

Mochida Pharmaceutical has licensed a portfolio of transient receptor potential vanilloid sub type 1 (TRPV1) receptor antagonists for use as a potential novel treatment for pain to Wyeth Pharmaceuticals.

Per the Agreement, Wyeth wins an exclusive worldwide license to develop, manufacture, use and sell pharmaceutical products containing Mochida's TRPV1 antagonists. Mochida will receive an upfront payment and potential development milestone payments, as well as royalties on sales by Wyeth.

Mochida retains an option to co-develop and co-market in Japan with Wyeth.

TRPV1 is a receptor and ion channel, which is stimulated by various stimuli including capsaicin, an ingredient derived from chilli peppers.

A number of other large pharmaceutical companies are also researching TRPV1 receptors for use in reducing nociception from inflammatory and neuropathic pain models in rats. In humans, drugs acting at TRPV1 receptors could potentially be used to treat neuropathic pain associated with multiple sclerosis, chemotherapy, or amputation, as well as pain associated with the inflammatory response of damaged tissue, such as in osteoarthritis. Existing painkillers sometimes cause gastrointestinal disorders or renal disorders, which limits their use.

14th January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...
How Helpful are Simple Health Messages?
...

Infographics